PONTE VEDRA BEACH, Fla., July 13, 2021—RedDress, a privately held, Israel and U.S. based wound care company, today announced that it will exhibit its innovative wound solution, the ActiGraft® system at the virtual WoundCon Summer 2021 on Friday, July 16, 2021. WoundCon is the first and largest global, virtual wound care conference that brings together healthcare professionals from all care settings to showcase the latest advancements and research in wound care.


ActiGraft, an FDA-cleared wound solution, was developed to treat chronic, hard-to-heal wounds by using a patient’s own blood to create – in real time – an in vitro blood clot. The autologous blood clot is then applied to the wound site to serve as a protective covering to the wound and support each stage of the body’s natural healing process.


RedDress will host a presentation to discuss the use of ActiGraft in the treatment of chronic wounds, followed by a live Q&A session. At the virtual exhibit hall, RedDress will feature a poster detailing the use of ActiGraft in a series of case studies.


“The cutting-edge technology harnessed in ActiGraft facilitates the process of revitalization in chronic and complex wounds to help improve patient outcomes while lessening the strain on providers” said Alon Kushnir, Founder and CEO of RedDress. “We are pleased to participate in WoundCon to exhibit ActiGraft and share tangible results and evidence which attests to the safety and efficacy of ActiGraft”.


Attendees are encouraged to visit RedDress’ virtual booth and attend RedDress sponsored events to learn more about how ActiGraft is used to support healing in chronic wounds and improve patient outcomes.



RedDress Sponsored Activities –



  • “The Utilization of an Autologous Blood Clot Tissue Matrix in the Treatment of Chronic Wounds in Patients with Diabetes”

Friday, July 16, 2021 - 9:00am-10:00am

Dr. Robert Snyder, DPM, MSc, CWS, FFPM RCPS


Booth Activity

  • “ActiGraft® System: Live Q&A with Dr. Robert Snyder”

Friday, July 16, 2021 - 10:30am-11:00am

Dr. Robert Snyder, DPM, MSc, CWS, FFPM RCPS


Exhibit Hall

  • “ActiGraft, an Autologous Blood Clot, Promotes Wound healing in Complex Surgical Wounds – A Case Series”

Exhibit Hours: 10:30am - 11:30am, 1:30pm - 2:30pm, 4:00pm - 5:00pm



About ActiGraft

The ActiGraft, based on RedDress’ proprietary patented technology, is an FDA-cleared wound care solution that enables health care providers to produce – in real time – an in vitro blood clot from a patient’s whole blood. Once applied, the blood clot serves as a protective covering and supports wound healing processes which naturally occur in the patient’s body.


ActiGraft is intended for exuding cutaneous wounds. ActiGraft includes blood-contacting components that have been sterilized by Ethylene Oxide, which may cause serious allergic reactions in patients that are sensitized. For full prescribing information, visit www.reddressmedical.com/safety-info.


About RedDress

RedDress (www.reddressmedical.com) is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients around the world with its latest innovation – ActiGraft.


Press and Media Inquiries:

Alessandra Lalli, RedDress



Investor Inquiries:

Russ Lalli, RedDress





ActiGraft® is a registered trademark of RedDress Ltd.